Marchesi Silvia, Marinello Arianna, Ambrosini Paolo, Cavalli Chiara, Lo Russo Giuseppe, Occhipinti Mario
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Department of Medical Oncology, International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France.
NPJ Precis Oncol. 2025 Jul 2;9(1):219. doi: 10.1038/s41698-025-01011-7.
Immune-checkpoint targeting Drug Conjugates (IDCs) are a novel class of therapeutics that combine an immune checkpoint-targeting moiety, a cleavable linker, and a cytotoxic payload. By integrating features and functions of antibody-drug conjugates and immunotherapy, IDCs represent a promising strategy to remodel the tumor microenvironment and enhance antitumor efficacy. Several IDCs targeting checkpoints such as PD-L1, B7-H3, and B7-H4 are in early-phase clinical trials. This review summarizes available data on IDC efficacy and toxicity in human. Although current evidence is limited, ongoing phase III trials and biomarker studies will clarify their optimal clinical role, including potential for tumor-agnostic use.
免疫检查点靶向药物偶联物（IDCs）是一类新型治疗药物，它将免疫检查点靶向部分、可裂解连接子和细胞毒性载荷结合在一起。通过整合抗体药物偶联物和免疫疗法的特性与功能，IDCs代表了一种重塑肿瘤微环境和增强抗肿瘤疗效的有前景的策略。几种靶向PD-L1、B7-H3和B7-H4等检查点的IDCs正处于早期临床试验阶段。本综述总结了关于IDCs在人体中的疗效和毒性的现有数据。尽管目前的证据有限，但正在进行的III期试验和生物标志物研究将阐明它们的最佳临床作用，包括肿瘤非特异性使用的潜力。
